Evidence map›Paper›PMID 31906484›Full record

ArticleGenes2020

Targeted Next-Generation Sequencing in Patients with Suggestive X-Linked Intellectual Disability.

Nekane Ibarluzea, Ana Belén de la Hoz, Olatz Villate, Isabel Llano, Intzane Ocio, Itxaso Martí, Miriam Guitart, Elisabeth Gabau, Fernando Andrade, Blanca Gener and 1 more

Abstract read
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Chromatin modifiers in neurodevelopment.Frontiers in molecular neuroscience · 2025
    Review
  6. Review
  7. Article
  8. Article
  9. Novel Genetic Variant inNeurology. Genetics · 2024
    Article
  10. Review
  11. Review
  12. Facial and ocular manifestations of male patients affected by theInternational journal of molecular epidemiology and genetics · 2023
    Review
  13. Variants inHGG advances · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. The different clinical facets ofFrontiers in cell and developmental biology · 2022
    Article
  20. Case Report: Identification of a novelFrontiers in genetics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nekane IbarluzeaBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Ana Belén de la HozBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Olatz VillateBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Isabel LlanoBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.ORCID 0000-0001-5576-1227
Intzane OcioDepartment of Paediatric Neurology, Araba University Hospital, Osakidetza Basque Health Service, 01009 Gasteiz, Spain.
Itxaso MartíDepartment of Paediatric Neurology, Donostia University Hospital, Osakidetza Basque Health Service, 20014 Donostia, Spain.
Miriam GuitartGenetics Laboratory, Paediatric Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.
Elisabeth GabauGenetics Laboratory, Paediatric Unit, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.
Fernando AndradeBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
Blanca GenerBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.
María-Isabel TejadaBiocruces Bizkaia Health Research Institute, 48903 Barakaldo, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

X-linked intellectual disability (XLID) is known to contribute up to 10% of intellectual disability (ID) in males and could explain the increased ratio of affected males observed in patients with ID. Over the past decade, next-generation sequencing has clearly stimulated the gene discovery process and has become part of the diagnostic procedure. We have performed targeted next-generation sequencing of 82 XLID genes on 61 non-related male patients with suggestive non-syndromic XLID. These patients were initially referred to the molecular genetics laboratory to exclude Fragile X Syndrome. The cohort includes 47 male patients with suggestive X-linked family history of ID meaning that they had half-brothers or maternal cousins or uncles affected; and 14 male patients with ID and affected brothers whose mothers show skewed X-inactivation. Sequencing data analysis identified 17 candidate variants in 16 patients. Seven families could be re-contacted and variant segregation analysis of the respective eight candidate variants was performed:

Indexed as

AdolescentAdultChildChild, PreschoolCohort StudiesExomeExome SequencingFragile X SyndromeGenes, X-LinkedGuanine Nucleotide Exchange FactorsHigh-Throughput Nucleotide SequencingHumansInfantIntellectual DisabilityMaleMediator ComplexGuanine Nucleotide Exchange FactorsIQSEC2 protein, humanMED12 protein, humanMediator ComplexMonoamine Oxidasemonoamine oxidase A, humanNerve Tissue ProteinsPlasma Membrane Neurotransmitter Transport ProteinsSLC6A8 protein, humanSLC9A6 protein, humanSodium-Hydrogen ExchangersTranscription Factorsgene panelHUWE1IQSEC2MED12next-generation sequencingPHF8SLC6A8SLC9A6SYN1X-linked intellectual disability

Identifiers

PMID31906484
PMCPMC7017351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.